

# **Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts**





Sonakshi Bhattacharjee, Florian Hamberger, Aashreya Ravichandra, Maximilian Miller, Silvia Affo, Ajay Nair, Aveline Filliol, LiKang Chin, Thomas M. Savage, Deqi Yin, Peter A. Sims, Ben Z. Stanger, Kenneth P. Olive, Naita Maren Wirsik, Nicholas Arpaia, Ekihiro Seki, Matthias Mack, Di Zhu, Thomas Schmidt, Rebecca G. Wells, Ingmar Mederacke and Robert F. Schwabe

## **SUPPLEMENTS FILES**




**Supplementary Figures S1-11**

**Supplementary Table S1-S3**



**Supplementary Methods and References**

**A****PDAC (Pan02)****B****PDAC (Pan02)****C****PDAC (Pan02)**









**Fig. S1 | Origin and characterization of CAF.** **A.** Representative image showing colocalization of Lrat-TdTomato with HSC marker desmin in Pan02 liver metastasis. Scale bars, 100 μm. **B.** Representative image displaying spatial organization of CK19-positive tumor cells with Lrat-TdTomato and Col1a1-GFP positive CAF in Pan02 liver metastasis. Scale bars, 100 μm. **C.** Representative images and quantification from confocal microscopy displaying LratCre-TdTomato and Col1a1-GFP. Col1a1-GFP hi cells are marked with a white arrowhead, Col1a1-GFP low cells are marked with a green arrowhead. n=8, Scale bars, 50 μm.

**A****B****C**








**Fig. S2 | CAF characterization through single cell RNA-sequencing.** **A.** Gating strategy used to sort CAF-enriched samples. 70% cells were taken from gate P6 (Col1a1-GFP positive) and 30% cells were from the live gate representing other populations. **B.** UMAPs showing genes used to determine panCAF signature in Pan02 and CMT93 liver metastasis model. **C.** iCAF, myCAF and mesCAF signatures and corresponding violin plots displaying all clusters with scores for iCAF, myCAF and mesCAF for Pan02 and CMT93 liver metastasis.


**D**

**E**


**Fig. S2 | CAF characterization through single cell RNA-sequencing (continued). D.** UMAPs showing genes used to determine panCAF signature in KPCY liver metastasis model. **E.** iCAF, myCAF and mesCAF signatures and corresponding violin plots displaying all clusters with scores for iCAF, myCAF and mesCAF for KPCY liver metastasis.



**Fig. S3 | CAF characterization through single cell RNA-sequencing in human liver metastasis.** **A.** UMAP showing cluster distribution of samples from 6 CRC liver metastasis patients. **B.** UMAP displaying all cell populations acquired in 1 human small intestinal neuroendocrine tumor (NET) liver metastasis sample. **C.** UMAPs of scRNA-seq of NET metastasis, displaying HSC and PF as a percentage of panCAF; human HSC markers *PDGFRB*, *GEM*, *HAND2*, *LUM* and human PF markers *MSLN* and *UPK1B*. **D.** UMAPs showing percentages and markers of myCAF and iCAF subpopulations for human NET liver metastasis. **E-F.** UMAPs showing genes used to determine panCAF signature and violin plots showing the clusters with panCAF scores for human CRC (E, n=6) and NET (Fn=1) liver metastasis. **G-H.** UMAPs showing genes used to determine iCAF, myCAF and mesCAF signatures and corresponding violin plots displaying all clusters with scores for iCAF, myCAF and mesCAF for human CRC (G, n=6) and NET liver metastasis (H, n=1).





**A****C****B****D****E****F****PDAC (KPCY)**

**Fig. S4 | CAF promote desmoplastic tumor growth.** HSC-CAF depletion via DT injection (0.5 ng/g) in LratCre+ TdTTom+,iDTR+ or LratCre+ TdTTom+ iDTR- littermates. **A.** mRNA levels of *Lrat* and *Colla1* are reduced within tumor tissue in LratCre+ TdTTom+,iDTR+ compared to LratCre+ TdTTom+ iDTR- littermates. mRNA levels are shown as fold induction in comparison to normal liver tissue. **B-C.** DT injection reduces TdT expression (B) but did not reduce body weight (C). **D.** mRNA levels of *Acta2* and *Colla1* are reduced within tumor tissue in αSMA-TK positive mice compared to αSMA-TK negative littermates in the Pan02 metastasis model (n=6-10 mice/group). mRNA levels are shown as fold induction in comparison to normal liver tissue. **E-F.** αSMA-TK positive mice and αSMA-TK negative littermates were injected intrasplenically with KPCY cells. Representative Sirius red images and quantification (E, n=9-13 mice/group). Scale bars, 100 μm. Representative macroscopic and CK19 IHC images of liver, liver body weight ratio (LBR), tumor area quantifications and Ki67 quantifications ( n=7 mice/group). Scale bars, 1cm (CK19) and 100 μm (Ki67). Statistics were done by two-tailed unpaired T-test or Mann Whitney-U. Data are displayed as mean ± SEM

**A**






PDAC (Pan02)

CRC (CMT93)

**B**




PDAC (Pan02)

CRC (CMT93)

**C****D**








PDAC (Pan02)

CRC (CMT93)




**E**

PDAC (Pan02)

CRC (CMT93)


**F**

**Fig. S5 | CAF promote tumor cell proliferation.** **A-B.** Effect of αSMA-TK-mediated CAF depletion in αSMA-TK positive mice and αSMA-TK negative littermates (n=7-8 mice per group) on metastatic growth of Pan02 and CMT93 metastasis. Ganciclovir injections were administered daily from day 10 to day 13. Representative macroscopic and IHC images of liver, liver body weight ratio (LBR) and tumor area quantifications of αSMA-TK positive mice and αSMA-TK negative littermates (B), scale bars, 1 cm. Representative IHC images and quantification of Ki67+ cells (B); scale bars, 100 μm. **C.** Representative IF images and quantification of Ki67+ GFP+ cells compared to Ki67+TdTom+HSC cells in the Pan02 model in LratCre+ TdTom+ mice; scale bars, 50 μm. **D-E.** Representative IHC images and quantification of cleaved caspase 3+ cells in Pan02 and CMT93 models in αSMA-TK positive mice and αSMA-TK negative littermates as described in A-B; scale bars, 100 μm. **F.** mRNA levels of *Pecam* and *Kdr* in αSMA-TK and Lrat-iDTR mice in the Pan02 model. mRNA levels are shown as fold induction in comparison to normal liver tissue (n=6-10 per group). Statistics were done by two-tailed unpaired T-test or Mann Whitney-U. Data are displayed as mean ± SEM , ns stands for p value not significant.

**A****B****C**



Isotype control

αSMA-TK Neg    αSMA-TK Pos




αCD8 antibody

αSMA-TK Neg    αSMA-TK Pos

**D**


Isotype control

αSMA-TK Neg    αSMA-TK Pos



αCD4 + αCD8 antibody

αSMA-TK Neg    αSMA-TK Pos



Isotype control

αSMA-TK NEG    αSMA-TK POS




CD4/CD8 depleted


αSMA-TK NEG    αSMA-TK POS







**Fig. S6 | Immune cell characterization in HSC-CAF depleted mice and CD8-depleted mice with liver metastasis.** **A.** Gating strategy of immune cells isolated from tumors from HSC-CAF depletion via DT injection (0.5 ng/g) at day 7 and day 10 in LratCre+ TdTom+, iDTR+ or LratCre+ TdTom+ iDTR- littermates. **B.** Immune cell population proportions as percent of CD45+ cells. **C.** Depletion efficiency of CD8 antibodies analyzed in blood samples collected from animals treated with antibody versus isotype control. **D.** CD4 and CD8 T-cell depletion or isotype injection in αSMA-TK mice injected with ganciclovir (i.p. 10 mg/kg) to deplete CAF simultaneously. Pan02 liver metastasis in αSMA-TK mice with representative macroscopic images of liver and liver body weight ratio (LBR) (n=5mice/group).





**Fig. S7 | Col1a1 is strongly upregulated in CAF and its deletion promotes metastatic tumor growth while decreasing stiffness.** **A.** Bulk RNA sequencing of purified quiescent HSC vs HSC-CAF shows top differentially expressed genes in HSC-CAF from Pan02, CMT93 and KPCY as ECM-associated. Top differentially expressed genes organized by log2fold change. **B.** mRNA levels of fibrosis-associated and immune cell-associated genes in *Col1a1<sup>f/f</sup>* vs *Col1a1<sup>ΔHSC</sup>* mice in the Pan02 model. mRNA levels are shown as fold induction in comparison to normal liver tissue. **C.** UMAPs and gene signatures of myCAF and *Colla1* in KPCY (n=1). Representative macroscopic and IHC images of liver, liver body weight ratio (LBR), tumor area quantifications Ki67 quantifications (n=7 mice/group) injected with KPCY cells in *Col1a1<sup>f/f</sup>* vs *Col1a1<sup>ΔHSC</sup>* mice. Scale bars, 1cm (CK19) and 100 $\mu$ m (Ki67). **D.** Sirius red (n= 10-12 mice/group) of Mx1Cre-induced *Colla1* deletion. Scale bars, 100  $\mu$ m. **E.** Representative macroscopic and IHC images of liver, liver body weight ratio (LBR), tumor area quantifications Ki67 quantifications (n=10-12 mice/group) injected with Pan02 cells in Mx1Cre<sup>pos</sup> x *Col1a1<sup>f/f</sup>* (*Col1a1<sup>ΔLiv</sup>*) vs *Col1a1<sup>f/f</sup>* littermates. Scale bars, 1cm (CK19) and 100  $\mu$ m (Ki67). **F.** Rheometry measurements in Mx1Cre<sup>pos</sup> x *Col1a1<sup>f/f</sup>* (*Col1a1<sup>ΔLiv</sup>*) mice injected with Pan02 cells showing reduced stiffness in comparison to *Col1a1<sup>f/f</sup>* littermates. Statistics were done by two-tailed unpaired T-test or Mann Whitney-U. Data are displayed as mean  $\pm$  SEM




**Fig. S8 | Hyaluronan promotes tumor cell growth.** (A) Bulk RNAseq data comparing top 30 differentially expressed genes between qHSC (from normal liver) and CAF derived from Pan02 (n=3), KPCY (n=3) and CMT93 (n=2) models. Genes organized by pAdj value relative to quiescent sample. (B) HA staining in desmoplastic Pan02 and CMT93 as well as non-desmoplastic E0771 and B16F10 liver metastasis. Scale bars, 100  $\mu$ m. (C) The majority of HA colocalizes with LratCre x TdTom-positive HSC and not to CK19-positive tumor cells. Scale bar, 50  $\mu$ m. (D) HA staining in LratCre<sup>pos</sup> TdTom<sup>pos</sup> iDTR<sup>pos</sup> mice or LratCre<sup>pos</sup> TdTom<sup>pos</sup> iDTR<sup>neg</sup> littermates, treated with 3x injections of DT (0.5 ng/g) reveals significantly reduced HA in HSC-CAF-depleted mice. Scale bar, 1 cm. (E) mRNA levels of Has2 are significantly decreased within tumor tissue in Has2  $\Delta$ HSC mice compared to Has2  $f/f$  mice injected intra-splenically with Pan02 cells, and not detected ("n.d.") in normal liver. Colla1 mRNA levels are shown as fold induction in comparison to normal liver tissue and not altered by Has2 deletion. Tu= Tumor, NL= Normal liver. (F) Sirius red staining reveals no differences in fibrosis between Has2  $f/f$  vs Has2  $\Delta$ HSC mice. Scale bars, 100  $\mu$ m. (G) UMAPs and gene signatures of myCAF and Has2 in KPCY (n=1). Representative macroscopic and IHC images of liver, the liver body weight ratio (LBR), tumor area and Ki67 quantifications (n=7-8 per group each) in Has2  $f/f$  vs Has2  $\Delta$ HSC mice in the KPCY liver metastasis model. Scale bars, 1 cm (CK19) and 100  $\mu$ m (Ki67). (H) To determine if CD4 and CD8 T cells were needed for tumor modulatory effects of HA, we investigated tumor development in the Pan02 liver metastasis model in Has2  $f/f$  vs Has2  $\Delta$ HSC mice that were depleted of CD4+ and CD8+ T cell by antibody injections day 6 and day 11. Shown are macroscopic and IHC images of liver, liver body weight ratio (LBR) and tumor area quantifications. Scale bars, 1 cm. Statistics were done by two-tailed unpaired T-test or Mann Whitney-U. Data are displayed as mean  $\pm$  SEM, ns stands for p value not significant.

**A****B****C****D**

**Fig. S9 | CAF expressed HGF links to tumor expressed MET and promotes tumor growth.** **A.** CellphoneDB analysis showing ligand-receptor interactions between tumor cells with CAF subpopulations- iCAF, myCAF and mesCAF. **B.** CellphoneDB analysis showing all Hgf-receptor interactions for iCAF against all populations. **C.** mRNA levels of *Lrat* and *Colla1* are unchanged within tumor tissue in Hgf<sup>ΔHSC</sup> mice compared to Hgf<sup>f/f</sup> mice injected with Pan02 cells. mRNA levels are shown as fold induction in comparison to normal liver tissue. **D.** UMAPs and gene signatures of iCAF and *Hgf* in KPCY (n=1). Representative macroscopic and CK19 and Ki67 IHC images of liver, liver body weight ratio (LBR), tumor area and Ki67 quantifications (n=4 per group each) in the KPCY model of liver metastasis. Statistics were done by two-tailed unpaired T-test or Mann Whitney-U. Data are displayed as mean ± SEM. Scale bars 1 cm (CK19) and 100 µm (Ki67).

**A****B**

**Fig. S10 | ScRNA-seq analysis of Col1a1 and Has2 co-expression in myCAF.** **A-B.** UMAPs showing co-expression of *Has2* and *Colla1* within myCAF populations in Pan02 (A) and CMT93 (B) metastasis models. Top 10% of each population is considered ‘High’.



**Fig. S11 | Comparison of endogenous KPC model with intra-splenic injected KPCY cells.** Histological comparison of liver metastasis in endogenous KPC model with intra-splenic injection of KPCY cells in the liver. Scale bars, 100 $\mu$ m



Angptl7	Celf2	Fth1	Il18	Msln	Rspo1	Slpi	Tnfaip3
Anxa3	Cpe	Gas6	Krt18	Ndrgr1	S100a1	Smpd3	Tnfrsf12a
Atp1b1	Cxadr	Gm20186	Krt7	Ndufa4	Saa3	Snrpg	Trf
Bicd1	Dab2	Gm8186	Krt8	Nkain4	Sbsn	Sprint2	Ucp2
C3	Ddr1	Gpc3	Ldhb	Pdgfc	Serpinb6b	Stmn1	Upk1b
Cd151	Ezr	Gpm6a	Lgals3	Pdpn	Shb	Tcea3	Upk3b
Cd200	Fbxo33	Hspbp1	Lrrn4	Rab11a	Slc39a8	Tmem151a	Wt1

HUMAN								
PanCAF	COL1A1	COL1A2	COL3A1	C1S	ACTA2	C1R	SERPINF1	PDGFRB
HSC	RGSS5	LUM	COLEC11	DCN	PDGFRB	GEM	TAGLN	CYGB
	EDNRA	EMILIN1	FOXS1	FRZB	HEYL	NDUFA4L2	NOTCH3	SEPT4
PF	MSLN	UPK1B	KRT19	SLPI				SERPINF1
Tumor	KRT19	EPCAM						
Endothelial	KDR	VWF	ERG					
Hepatocyte-like	ALB	TTR						
T cell	CD3E	CD3D	CD3G	CD8A				
B cell	CD79A	CD79B						
Plasma cell	JSRP1	FCRL5						
Mast cell	CPA3	TPSAB1	KIT					
DC-like cell	ITGAX							
Monocytes	CD68	CD74	CD14	CSF1R				
Macrophaged	VSIG4	CD68	FCGR2A	CD163				

HUMAN myCAF	APOD	CCL11	COL1A1	COL1A2	COL3A1	COL5A1	COL6A3	CTGF	CTHRC1	CYP1B1	FN1
INHBA	ISLR	LUM	MMP14	POSTN	PTGDS	SERPINF1	SFRP2	SPON2	VCAN		

HUMAN iCAF									
ADAMTS4	AGT	APOE	ARHGDB	CCL19	CCL21	COLEC11	CPE	GEM	GJA4
GPX3	HIGD1B	IL6	ISYNA1	IHEP	MAP1B	MT1A	NDUFA4L2	PDK4	RGS5

**Table S2. Top HSC-CAF/tumor interactions in CRC and PDAC liver metastasis.**

Combined Rank Pan02, KPCY and CMT93	Interacting ligand-receptor pair	Rank Pan02	Significant means HSC-CAF/tumor interactions (Pan02)	Rank KPCY	Significant means HSC-CAF/tumor interactions (KPCY)	Rank CMT93	Significant means HSC-CAF/tumor interactions (CMT93)
1	COL3A1_DDR1	2	37.435	3	23.842	1	41.029
2	COL3A1_a2b1 complex	3	37.405	1	24.078	3	40.783
3	COL3A1_DDR2	1	37.484	4	23.626	2	40.818
4	COL3A1_a1b1 complex	4	37.391	2	23.861	4	40.757
5	<b>COL1A1_DDR1</b>	10	<b>17.063</b>	7	<b>20.402</b>	5	<b>26.889</b>
6	<b>COL1A1_a2b1 complex</b>	11	<b>17.033</b>	5	<b>20.637</b>	7	<b>26.643</b>
7	<b>COL1A1_DDR2</b>	9	<b>17.112</b>	8	<b>20.186</b>	6	<b>26.677</b>
8	<b>COL1A1_a1b1 complex</b>	12	<b>17.019</b>	6	<b>20.42</b>	8	<b>26.617</b>
9	COL1A2_DDR1	6	18.767	11	18.666	9	24.247
10	COL1A2_a2b1 complex	7	18.737	9	18.901	11	24.001
11	COL1A2_DDR2	5	18.816	12	18.45	10	24.036
12	COL1A2_a1b1 complex	8	18.724	10	18.684	12	23.975
13	FN1_a3b1 complex	14	3.617	13	11.382	14	3.842
14	COL14A1_a2b1 complex	13	6.102	21	3.722	13	4.727
15	FN1_a2b1 complex	17	3.418	14	11.231	16	3.626
16	FN1_a2Bb3 complex	15	3.508	16	10.776	17	3.569
17	FN1_a4b7 complex	18	3.381	15	10.786	15	3.677
18	COL5A2_DDR1	22	2.585	20	3.861	18	3.546
19	COL6A3_a2b1 complex	16	3.493	22	3.523	22	3.108
20	COL4A1_DDR1	20	2.826	18	6.358	24	2.669
21	COL5A2_a2b1 complex	23	2.555	19	4.097	20	3.3
22	COL4A1_a2b1 complex	21	2.796	17	6.593	26	2.423
23	LAMP1_FAM3C	19	3.33	29	2.094	19	3.487
24	COL5A1_DDR1	25	2.157	26	3.179	25	2.519
25	COL5A1_a2b1 complex	26	2.127	24	3.414	27	2.273
26	THBS1_a3b1 complex	30	1.803	30	1.969	21	3.231
27	COL6A2_a2b1 complex	24	2.493	33	1.636	31	1.837
28	<b>HGF_CD44</b>	29	<b>1.864</b>	28	<b>2.366</b>	34	<b>1.453</b>
29	COL4A2_a2b1 complex	36	1.499	25	3.311	33	1.548
30	COL4A2_DDR1	35	1.529	27	3.076	32	1.794
31	MMP2_aVb3 complex	27	1.958	45	0.915	23	2.888
32	TNFSF12_TNFRSF12A	33	1.612	34	1.578	28	2.243
33	COL15A1_a2b1 complex	40	0.971	23	3.51	40	0.985
34	LGALS9_CD44	37	1.194	32	1.738	37	1.333
35	IGF1_IGF1R	28	1.908	50	0.756	29	2.081
36	IGF1_a6b4 complex	31	1.775	42	1.051	35	1.399
37	LAMC1_a6b1 complex	38	1.01	31	1.75	42	0.955
38	VCAM1_a4b7 complex	34	1.598	51	0.729	30	1.907
39	RSPO3_LGR6	32	1.695	43	1.032	41	0.985
40	HAS1-HA-ligand_CD44	41	0.865	40	1.187	39	1.004
41	LAMC1_a2b1 complex	39	1.01	37	1.269	46	0.921
42	FGF2_CD44	44	0.735	36	1.281	44	0.928
43	<b>HAS2-HA-ligand_CD44</b>	47	<b>0.626</b>	35	<b>1.282</b>	45	<b>0.925</b>
44	TNC_aVb6 complex	50	0.435	44	1.012	38	1.012
45	MDK_SORL1	46	0.675	53	0.617	36	1.363
46	COL12A1_a2b1 complex	51	0.39	46	0.906	43	0.948
47	LGALS9_MET	45	0.713	48	0.815	48	0.729
48	COL8A1_a2b1 complex	52	0.368	41	1.165	49	0.706
49	PROS1_TYRO3	42	0.856	54	0.579	47	0.857
50	COL16A1_a2b1 complex	49	0.467	47	0.837	51	0.514
51	TGFB1_aVb6 complex	56	0.308	39	1.229	52	0.446
52	COL6A5_a2b1 complex	43	0.752	55	0.522	50	0.571
53	COL5A3_a2b1 complex	60	0.273	38	1.238	62	0.245
54	COL27A1_a2b1 complex	54	0.358	52	0.706	55	0.328
55	CSPG4_a3b1 complex	57	0.293	49	0.764	57	0.296
56	CADM3_EPB41L1	48	0.525	63	0.222	53	0.411
57	COL6A6_a2b1 complex	53	0.363	57	0.484	54	0.368
58	EPHB2_EFNB2	55	0.346	61	0.273	60	0.249
59	NOTCH1_DLL4	59	0.276	59	0.38	59	0.251
60	NOTCH1_JAG2	58	0.287	58	0.422	61	0.248
61	<b>HAS2-HA-ligand_HMMR</b>	62	<b>0.236</b>	62	<b>0.269</b>	56	<b>0.319</b>
62	NRG1_a6b4 complex	64	0.157	56	0.505	65	0.12
63	NOTCH3_JAG2	63	0.229	60	0.35	63	0.217
64	IL1 receptor inhibitor_IL1	65	0.11	65	0.175	58	0.285
65	EPHB6_EFNB2	61	0.267	64	0.211	64	0.187
66	NOTCH4_JAG2	66	0.025	66	0.122	66	0.058

**Table S3. 43 novel CellPhoneDB ligand-receptor interactions.**

Ligand-receptor	Ligand Name	Ligand ID	Receptor name	Receptor ID	PMID Reference
COL1A1 - DDR1	COL1A1	P02452	DDR1	Q08345	PMID: 32047176 ; PMID: 32244515 ; PMID: 28590245 ; PMID: 31004686
COL1A2 - DDR1	COL1A2	P08123	DDR1	Q08345	PMID: 32047176 ; PMID: 32244515 ; PMID: 28590245 ; PMID: 31004686
COL2A1 - DDR1	COL2A1	P02458	DDR1	Q08345	PMID: 33234027 ; PMID: 31004686
COL3A1 - DDR1	COL3A1	P02461	DDR1	Q08345	PMID: 28743124 ; PMID: 31004686 ; PMID: 21421911
COL5A1 - DDR1	COL5A1	P20908	DDR1	Q08345	PMID: 33234027 ; PMID: 31004686 ; PMID: 23861322
COL5A2 - DDR1	COL5A2	P05997	DDR1	Q08345	PMID: 23861322
COL5A3 - DDR1	COL5A3	P25940	DDR1	Q08345	PMID: 23861322
COL11A1 - DDR1	COL11A1	P12107	DDR1	Q08345	PMID: 31717573
COL11A2 - DDR1	COL11A2	P13942	DDR1	Q08345	PMID: 31717573
COL1A1 - DDR2	COL1A1	P02452	DDR2	Q16832	PMID: 31699892 ; PMID: 21421911
COL1A2 - DDR2	COL1A2	P08123	DDR2	Q16832	PMID: 31699892 ; PMID: 21421911
COL2A1 - DDR2	COL2A1	P02458	DDR2	Q16832	PMID: 31958497
COL3A1 - DDR2	COL3A1	P02461	DDR2	Q16832	PMID: 28743124 ; PMID: 21421911
COL5A1 - DDR2	COL5A1	P20908	DDR2	Q16832	PMID: 33234027 ; PMID: 23861322
COL5A2 - DDR2	COL5A2	P05997	DDR2	Q16832	PMID: 23861322
COL5A3 - DDR2	COL5A3	P25940	DDR2	Q16832	PMID: 23861322
COL11A1 - DDR2	COL11A1	P12107	DDR2	Q16832	PMID: 29769618
COL11A2 - DDR2	COL11A2	P13942	DDR2	Q16832	PMID: 31717573
COL4A1 - DDR1	COL4A1	P02462	DDR1	Q08345	PMID: 23861322
COL4A2 - DDR1	COL4A2	P08572	DDR1	Q08345	PMID: 23861322
COL4A3 - DDR1	COL4A3	Q01955	DDR1	Q08345	PMID: 23861322
COL4A4 - DDR1	COL4A4	P53420	DDR1	Q08345	PMID: 23861322
COL4A5 - DDR1	COL4A5	P29400	DDR1	Q08345	PMID: 23861322
COL4A6 - DDR1	COL4A6	Q14031	DDR1	Q08345	PMID: 23861322
COL10A1 - DDR2	COL10A1	Q03692	DDR2	Q16832	PMID: 3324550
HAS1-HA - CD44	HAS1-HA-ligand	Undefined	CD44	P16070	PMID: 24406795 ; PMID: 31276783 ; PMID: 18661346
HAS1-HA - HMMR	HAS1-HA-ligand	Undefined	HMMR	O75330	PMID: 31276783 ; PMID: 24668563
HAS1-HA - ICAM1	HAS1-HA-ligand	Undefined	ICAM1	P05362	PMID: 16449361 ; PMID: 8867647
HAS1-HA - TLR4	HAS1-HA-ligand	Undefined	TLR4	O00206	PMID: 21248167 ; PMID: 31484704
HAS1-HA - TLR2	HAS1-HA-ligand	Undefined	TLR2	O60603	PMID: 21248167 ; PMID: 28682809 ; PMID: 20534434
HAS1-HA - LYVE1	HAS1-HA-ligand	Undefined	LYVE1	Q9Y5Y7	PMID: 12554094 ; PMID: 19033446 ; PMID: 30054204
HAS2-HA - CD44	HAS2-HA-ligand	Undefined	CD44	P16070	PMID: 24406795 ; PMID: 31276783 ; PMID: 18661346
HAS2-HA - HMMR	HAS2-HA-ligand	Undefined	HMMR	O75330	PMID: 31276783 ; PMID: 24668563 ; PMID: 30365189
HAS2-HA - ICAM1	HAS2-HA-ligand	Undefined	ICAM1	P05362	PMID: 16449361 ; PMID: 8867647
HAS2-HA - TLR4	HAS2-HA-ligand	Undefined	TLR4	O00206	PMID: 21248167 ; PMID: 31484704
HAS2-HA - TLR2	HAS2-HA-ligand	Undefined	TLR2	O60603	PMID: 21248167 ; PMID: 28682809 ; PMID: 20534434
HAS2-HA - LYVE1	HAS2-HA-ligand	Undefined	LYVE1	Q9Y5Y7	PMID: 12554094 ; PMID: 19033446 ; PMID: 30054204
HAS3-HA - CD44	HAS3-HA-ligand	Undefined	CD44	P16070	PMID: 24406795 ; PMID: 31276783 ; PMID: 18661346
HAS3-HA - HMMR	HAS3-HA-ligand	Undefined	HMMR	O75330	PMID: 31276783 ; PMID: 24668563 ; PMID: 30365189
HAS3-HA - ICAM1	HAS3-HA-ligand	Undefined	ICAM1	P05362	PMID: 16449361 ; PMID: 8867647
HAS3-HA - TLR4	HAS3-HA-ligand	Undefined	TLR4	O00206	PMID: 21248167 ; PMID: 31484704
HAS3-HA - TLR2	HAS3-HA-ligand	Undefined	TLR2	O60603	PMID: 21248167 ; PMID: 28682809 ; PMID: 20534434
HAS3-HA - LYVE1	HAS3-HA-ligand	Undefined	LYVE1	Q9Y5Y7	PMID: 12554094 ; PMID: 19033446 ; PMID: 30054204

## **SUPPLEMENTARY METHODS**

### **RNA isolation and real-time qPCR**

Total tissue and cell RNA was isolated using TRIZOL and Tissue RNA isolation kit (Roche or Qiagen). RNA (1 µg) was reverse transcribed using TaqMan Reverse transcription reagent kit (Roche). Primers were designed in conjunction with the appropriate ABI probes (Applied Biosystems) and the samples were then used for real-time qPCR performed on PCR on Applied Biosystems™ QuantStudio™ 5 Real-Time PCR System (Applied Biosystems). Absolute values were quantified using relative standard curves, normalized to 18s expression and fold inductions were carried out with respect to livers of Naïve mice.

### **Bulk RNA sequencing**

RNA from ultrapure HSC-CAF and quiescent samples was extracted using the RNeasy Micro or Mini Kit (Qiagen) with on-column DNase digestion accordingly to manufacturer instructions. RNA (RNA integrity number [RIN] >8, as determined by Bioanalyzer 2100, Agilent Technologies) was used to construct libraries using Illumina TruSeq RNA Preparation Kit according to the manufacturer's instructions. 20M paired-end 100bp sequencing was performed using the Illumina NovaSeq 6000 at Columbia Genome Center. RTA (Illumina) was used for base calling and bcl2fastq2 (version 2.19) for converting BCL to fastq format, coupled with adaptor trimming. A pseudoalignment to a kallisto index was created from transcriptomes (Human: GRCh38; Mouse: GRCm38) using kallisto (0.44.0). Differentially expressed genes were tested using DESeq2. Normalization was done internally using DESeq2's specialized algorithm and

normalization to compare across samples, was performed using the TPM (transcripts per million) method.

### **Single-cell RNA sequencing**

Murine single-cell RNA-seq was performed on cells isolated from mice with Pan02 and CMT 93 liver metastasis as described below. Single-cell RNA-seq data from human CRC liver metastasis (*I*) and NET (*2*) have been previously published. CAF-enriched but multiple cell populations from Pan02 and CMT93 were obtained following the isolation protocol described above for CAF from Lrat-Cre+ TdTom+ Col1a1-GFP+ mice. In order to obtain CAF-enriched samples along with several other cell populations for CellPhoneDB analysis, we combined Col1a1-GFP+ cells (70%) with the unpurified live cell suspension (30%) by sorting on a BD Aria II Cell Sorter. Mouse tumor specimens were processed as previously described and freshly isolated cells were counted on Countess II automated cell counter (ThermoFisher) and were loaded on a 10x Chromium instrument (10x Genomics). Single-cell RNA-seq libraries were prepared using the Chromium Single Cell 3' v3 Reagent Kit (10x Genomics) according to manufacturer's instructions. 12 cycles of cDNA amplification and 12 cycles of library amplification were performed, and samples were sequenced on an Illumina NovaSeq 6000 Sequencing System at the JP Sulzberger Columbia Genome Center. 10x Genomics Cellranger pipeline was used to process the data. BCL files were demultiplexed with 10x Cell Ranger's mkfastq command and analysis and alignment were performed using Cell Ranger's count command with Cell Ranger's reference mm10. Single-cell count matrices for both mouse and the human samples, were loaded into scanpy AnnData objects (scanpy v1.4.6). QC metrics (total number of counts, number of genes detected, percentage of mitochondrial RNA) was used to identify and remove outliers in the distribution of cells, cells with

high mitochondrial content (>40%) were excluded (3). Each cell was normalized using pool-derived size factors (4) and log-transformed each matrix. Principal component analysis was performed on the resulting matrices (scanpy v1.4.6). To identify cell sub-populations, we employed the Louvain algorithm for community detection (5) with different values for the resolution parameter, analyzing the average Silhouette score across all cells for each clustering (6). Differentially expressed genes were computed using the Wilcoxon Rank-Sum test as implemented in scanpy, and the different populations were labeled based on the genes differentially up-regulated in each population. Cell populations including CAF, hepatocytes, T and B lymphocytes, dendritic cells, endothelial cells, myeloid cells, monocytes and neutrophils, were identified using specific markers genes (Table S1) and confirmed by PanglaoDB (7). Mouse scores for panCAF and CAF subpopulations signatures were computed as previously defined (8). Clusters having at least 50% of cells with positive pan-CAF score were considered further for analysis of CAF subtypes. HSC-CAF and PF-CAF scores were calculated using the HSC and PF signatures in Table S1 and percentages were calculated for each sample. For mouse signatures, within panCAF, CAF subpopulation score distributions were analyzed, and a CAF subpopulation label was assigned to each cell if the corresponding score was higher than 0.125 (to reduce the number of cells with multiple labels). A signature for different CAF subpopulations by selecting differentially expressed genes between the different subpopulations ( $q < 0.05$ ,  $\log\text{-FC} > 1$ ) was computed on single-CAF for each sample and 3 different populations were identified and named as iCAF, myCAF and mesCAF accordingly to their DGE and pathways enrichment as described in Results. The gene signature was analyzed in all cell populations to ensure the signature was specific to the particular CAF subset. Human panCAF and CAF subpopulation signatures were identified in “Human CRC metastasis and Human NET metastasis” datasets using the following procedure.

Literature-defined CAF signatures (8) and the mouse CAF signatures were used to define the cell clusters corresponding to panCAF and CAF subpopulations. panCAF signature was computed by obtaining the differentially expressed genes ( $q < 0.05$ ,  $\log\text{-FC} > 1$ ) in PAN-CAF cluster compared to all other cell types and manually selecting genes with panCAF specific expression. HSC-CAF and PF-CAF were determined as previously described and CAF subpopulations iCAF, myCAF and mesCAF signatures were computed by obtaining the differentially expressed genes ( $q < 0.05$ ,  $\log\text{-FC} > 1$ ) in the respective CAF subpopulation compared to the rest of panCAF and were independently validated by their differential gene expression and GO enrichment analysis (iCAF, myCAF and mesCAF human signatures are shown in Extended Data Table S1). These panCAF and CAF subpopulation signatures were then reapplied to the human sample to obtain and quantify CAF populations as mentioned previously. Notably, no mesCAF population was detected in the human samples.

## CellPhoneDB Analysis

CellPhoneDB (9), a curated repository of ligands, receptors, their subunit interactions was used to identify ligand-receptor interactions in the three mouse models and human liver metastasis single cell RNAseq samples. Following identification of different cell types in our scRNA-seq datasets as described above, we followed recommended protocols for preparation of input files using CellPhoneDB v.2.0.0 (9). We updated the original CellPhoneDB repository with 43 novel interactions and 3 complexes curated from literature using ‘cellphonedb database generate’ command (Extended Data Table S3 provides Pubmed IDs with literature documenting the added interactions). All CellPhoneDB statistical analysis were performed with a percentage cell expression threshold of 1%. Cell-cell interactions heatmaps were generated using pheatmap R

package and ligand-receptor interactions were visualized using ggplot2 R package. Top common ligand receptor pairs between HSC-CAF and tumor cells were sorted based on significant means (p value <0.05) shown in Extended Data Table S4.

## Rheometry

Tumor samples were extracted from liver specimens using a stainless-steel punch when >8mm, and cylindrical samples were cut manually and the diameter was determined from optical images. Parallel plate shear rheometry was carried out using a Kinexus rheometer (Malvern Panalytical, Westborough, MA). Samples were attached to the top and bottom plates with fibrin glue made by mixing 10 µl of 5 mg/ml salmon fibrinogen and 10 µl of 150 U/ml salmon thrombin (Sea Run Holdings, Freeport, ME) for each side of the sample. The top plate (8 mm diameter) was lowered until contact was made as determined by the application of 400 Pa normal stress, and the sample was allowed to rest for 5 min to ensure attachment to the metal plates. Shear storage modulus G', loss modulus G'', and normal force were measured by applying a low oscillatory shear strain of 2% at a frequency of 1 rad/sec at room temperature. Simultaneously, samples were subjected to small stepwise axial strains in tension (0, 10, and 20%) followed by compression (-10, -15, -20, and -25%), between which the samples were allowed to relax for 2 min. The equilibrium G' and G'' after 2 min of relaxation were plotted against axial strain.

Samples were always kept moist during experiments using PBS.

## SUPPLEMENTARY REFERENCES

1. Y. Zhang, J. Song, Z. Zhao, M. Yang, M. Chen, C. Liu, J. Ji, D. Zhu, Single-cell transcriptome analysis reveals tumor immune microenvironment heterogeneity and granulocytes enrichment in colorectal cancer liver metastases. *Cancer Lett* **470**, 84-94 (2020).
2. M. Rao, K. Oh, R. Moffitt, P. Thompson, J. Li, J. Liu, A. Sasson, G. Georgakis, J. Kim, M. Choi, S. Powers, Comparative single-cell RNA sequencing (scRNA-seq) reveals liver metastasis-specific targets in a patient with small intestinal neuroendocrine cancer. *Cold Spring Harb Mol Case Stud* **6**, (2020).
3. T. Ilicic, J. K. Kim, A. A. Kolodziejczyk, F. O. Bagger, D. J. McCarthy, J. C. Marioni, S. A. Teichmann, Classification of low quality cells from single-cell RNA-seq data. *Genome Biol* **17**, 29 (2016).
4. A. T. Lun, K. Bach, J. C. Marioni, Pooling across cells to normalize single-cell RNA sequencing data with many zero counts. *Genome Biol* **17**, 75 (2016).
5. G. J.-L. Blondel VD, Lambiotte R, Lefebvre E., Fast unfolding of communities in large networks. *J. Stat. Mech. Theory Exp.* **10008:6**, (2008).
6. P. J. Rousseeuw, Silhouettes: a graphical aid to the interpretation and validation of cluster analysis. *Journal of computational and applied mathematics* **20** (1987): 53-65, (1987).
7. L.-M. G. a. J. L. M. B. r. Oscar Franzén, PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data. *Database* **2019**, 1-9, (2019).
8. E. Elyada, M. Bolisetty, P. Laise, W. F. Flynn, E. T. Courtois, R. A. Burkhardt, J. A. Teinor, P. Belleau, G. Biffi, M. S. Lucito, S. Sivajothy, T. D. Armstrong, D. D. Engle, K. H. Yu, Y. Hao, C. L. Wolfgang, Y. Park, J. Preall, E. M. Jaffee, A. Califano, P. Robson, D. A. Tuveson, Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. *Cancer Discov* **9**, 1102-1123 (2019).
9. R. Vento-Tormo, M. Efremova, R. A. Botting, M. Y. Turco, M. Vento-Tormo, K. B. Meyer, J. E. Park, E. Stephenson, K. Polanski, A. Goncalves, L. Gardner, S. Holmqvist, J. Henriksson, A. Zou, A. M. Sharkey, B. Millar, B. Innes, L. Wood, A. Wilbrey-Clark, R. P. Payne, M. A. Ivarsson, S. Lisgo, A. Filby, D. H. Rowitch, J. N. Bulmer, G. J. Wright, M. J. T. Stubbington, M. Haniffa, A. Moffett, S. A. Teichmann, Single-cell reconstruction of the early maternal-fetal interface in humans. *Nature* **563**, 347-353 (2018).